09.01.2014 09:33
Bewerten
 (0)

Press Release: BioCrea Wins The Epilepsy Innovation Seal of Excellence Award

BioCrea / BioCrea Wins The Epilepsy Innovation Seal of Excellence Award . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Radebeul, Germany, January 9, 2014 - BioCrea GmbH (BioCrea), the first-in-class CNS drug discovery specialist validated through pharma partnerships, announced today that the Epilepsy Foundation (Maryland, US) has presented the Epilepsy Innovation Seal of Excellence Award to BioCrea in recognition of the creation of the new anti-seizure platform, Novel Long Term Effective GABA(A) PAMs (LT GABA(A) PAM), to treat refractory epilepsy.

"We are delighted to receive the prestigious SEAL award," said Dr. Tom Kronbach, CEO of BioCrea. "This recognition by the Epilepsy Foundation for our work on the LT GABA(A) PAM platform is highly appreciated. We are impressed that the Foundation's Scientific Advisory Board and Business Advisory Board do see the potential for our platform to deliver efficacious and novel epilepsy treatments which are currently at candidate selection stage. Having successfully delivered novel treatments for partners such as Pfizer, GlaxoSmithKline, Wyeth and Boehringer Ingelheim, we are well placed to further build our portfolio of projects."

The Epilepsy Foundation stated in a letter to BioCrea: "This award is based on the enthusiasm of the Epilepsy Foundation's Scientific Advisory Broad and Business Advisory Board for the present accomplishments and future potential of this new drug platform that we hope will alleviate the suffering of persons with epilepsy."

About BioCrea

BioCrea, the Radebeul-based first-in-class drug discovery specialist validated through pharma partnerships, has established a number of programs in neurological and psychotic disorders. Its proven expertise is based on proprietary compound libraries, medicinal chemistry, molecular modeling and advanced screening technologies. BioCrea uses this expertise in an innovative multi-parameter optimization approach to generate and deliver CNS drug candidates that offer significant potential for greater efficacy and tolerability. Moreover, the patient-derived stem cell (iPSC) platform has been successfully developed to discover high value preclinical drug candidates for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease). BioCrea was awarded Top Innovator status of the "Top 100" Most Innovative Companies in Germany 2012 by compamedia GmbH.

About the Epilepsy Foundation

The Epilepsy Foundation, a national non-profit with 47 affiliated organizations throughout the United States, has led the fight against seizures since 1968. The Foundation is an unwavering ally for individuals and families impacted by epilepsy and seizures. The Foundation works to prevent, control and cure epilepsy through community services; public education; federal and local advocacy; and supporting research into new treatments and therapies. The Foundation works to ensure that people with seizures have the opportunity to live their lives to their fullest potential. For additional information, please visit: www.epilepsy.com.

Contact

Dr. Tom Kronbach

CEO, BioCrea GmbH

Tel.: +49 351 / 4043 3332

Fax: +49 351 / 4043 3216

tom.kronbach@biocrea.com

Press Release PDF: http://hugin.info/156612/R/1753539/591527.pdf

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: BioCrea via Globenewswire

HUG#1753539

--- End of Message ---

BioCrea

BioCrea GmbH Radebeul Germany

http://www.biocrea.com (END) Dow Jones Newswires

   January 09, 2014 03:00 ET (08:00 GMT)- - 03 00 AM EST 01-09-14

Anzeige
Börse Stuttgart Anlegerclub
Technologieaktien: Drei Möglichkeiten, um vom Trend "Digitale Fabrik" zu profitieren!
Die vierte industrielle Revolution ist im vollen Gange und verändert, vom Großteil der Gesellschaft völlig unbemerkt, bereits die Produktionsabläufe in den großen, industriellen Hallen. Wir zeigen Ihnen in der aktuellen Ausgabe des Anlegermagazins drei Möglichkeiten, wie Sie in den kommenden Monaten und Jahren von dem Zukunftstrend "Digitale Fabrik" profitieren können.
Anlegermagazin kostenlos erhalten

Heute im Fokus

DAX schließt um Nulllinie -- US-Börsen schwächer -- Draghi verteidigt lockere Geldpolitik -- EZB-Leitzins bleibt unverändert -- Netflix Umsatzsprung erfreut Anleger -- VW, Fresenius im Fokus

Spannung vor dem Eid: Trump übernimmt die Macht in Washington. Goldman Sachs, UBS & Co. bringen wegen Brexit wohl Tausende Jobs nach Frankfurt. Experte der Bank of America: Jeder Forex-Trader braucht jetzt einen Twitter-Account. Haustürgeschäfte, falsche Rechnungen, Kundenhotlines: Diese Rechte haben Verbraucher.
Diese 10 Automobil Neuheiten gibt es bei der Detroit Auto Show 2017
Jetzt durchklicken
Diese Aktien stehen auf den Verkauflisten der Experten
Jetzt durchklicken
Diese 10 Aktien kann sich nicht jeder Investor leisten
Jetzt durchklicken

Die 5 beliebtesten Top-Rankings

Die Millionen-Dollar-URLs
Jetzt durchklicken
Welche Commodities entwickelten sich 2016 am stärksten?
Jetzt durchklicken
Mit diesem Studium wird man CEO im Dow Jones
Jetzt durchklicken
Das verdienen YouTube-Stars mit Videos
Jetzt durchklicken
So reich sind die Minister aus Donald Trumps Kabinett
Jetzt durchklicken
mehr Top Rankings

Umfrage

Der künftige US-Präsident Donald Trump hat die Nato als obsolet bezeichnet. Halten Sie das Militärbündnis ebenfalls für überflüssig?
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Goldpreis
Meistgesucht
Volkswagen AG Vz. (VW AG) 766403
Deutsche Bank AG 514000
Daimler AG 710000
BASF BASF11
Commerzbank CBK100
Bayer BAY001
Nordex AG A0D655
E.ON SE ENAG99
Apple Inc. 865985
Netflix Inc. 552484
Allianz 840400
Deutsche Telekom AG 555750
K+S AG KSAG88
Siemens AG 723610
Tesla A1CX3T